Antiphospholipid antibodies negativization: Time for testing for non-criteria aPL?

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1727961 since 2020-02-18T12:03:47Z

Published version:
DOI:10.1177/0961203317711014

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This is the author's final version of the contribution published as:

Antiphospholipid antibodies negativization: time for testing for non-criteria aPL?
Radin M, Cecchi I, Pérez-Sánchez C.

The publisher's version is available at:

When citing, please refer to the published version.

Link to this full text:
http://hdl.handle.net/2318/1727961
Antiphospholipid Antibodies Negativization: time for testing for non-criteria aPL?

Massimo Radin\textsuperscript{1}, Irene Cecchi\textsuperscript{1}, Carlos Pérez-Sánchez\textsuperscript{2}

\textsuperscript{1}Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy

\textsuperscript{2}Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.

\textbf{Running Title:} aPL negativization: non-criteria aPL testing?

\textbf{Key words:}


\textbf{Corresponding Author:}

Massimo Radin, MD;

Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital

Piazza del Donatore di Sangue 3, 10154, Turin, Italy.

Email massimo.radin@unito.it  Tel +390112402056 Fax +390112402052

This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation
Dear Editor,

while we read with interest the recent article by Comarmond and Colleagues\(^1\) about cessation of oral anticoagulants in AntiPhospholipidSyndrome (APS), we do feel there are some points of the study still open for discussion.

Comarmond and Colleagues\(^1\) describe 10 patients with prolonged disappearance of antiphospholipid antibodies (aPL) that were stopped anticoagulation therapy. After a median duration of follow-up of 19 months since the cessation of oral anticoagulant, one out of 10 patients relapsed developing pulmonary embolism.

Recent findings contribute to the hypothesis that persistent negative aPL profile is not an indication to interrupt oral anticoagulant therapy.

Medina and colleagues\(^2\), investigated aPL negativization in a retrospective study in a large cohort of 70 patients with primary APS. Patients were tested for the presence of aPL, including anti-annexin A5 antibodies, and, when found negative, patients were re-tested after 5 years to confirm the disappearance of autoantibodies. Persistent negativization of aPL was detected in 24/70 patients. Since aPL disappearance and after 60 months of follow-up, 11 out of 24 patients (45.8%) presented recurrence of thrombosis despite the anticoagulant treatment.

Laboratory criteria for APS include the assays test for the presence of lupus anticoagulant, anticardiolipin antibodies (aCL) and anti-β2GPI antibodies (anti-β2GPI)\(^3\). However, in patients with persistent disappearance of aPL, a second level screening of non-criteria aPL should be strongly encouraged before stopping the anticoagulant treatment.

For instance, the use of IgA isotypes for both aCL and anti-β2GPI are not a part of the routine diagnostic algorithm\(^4\). However, some data suggested a role of isolated positivity for IgA anti-β2GPI with clinical APS symptoms might help to identify additional patients who are at risk of developing thrombotic events, recommending these tests when other aPL are negative\(^4\).
Furthermore, among the so-called extra-criteria aPL tests, anti-phosphatidylycerine/prothrombin antibodies and anti-β2GPI glycoprotein-I domain1 antibodies have been proposed to potentially improve the diagnostic accuracy, especially when assessing the risk for both thrombosis and pregnancy morbidities in patients suspected of APS. Other antibody specificities, such as anti-annexin A5 and antivimentin antibodies, might be considered for thrombotic risk assessment only in selected patients, particularly when other aPL tests are negative and in the presence of clinical APS signs and/or symptoms. Indeed, further investigations are needed to assess their role in the diagnostic algorithm for APS. Moreover, it would be of great interest to establish an accurate definition of disappearance of aPL, since it might be important to specify for how long and how many negative tests must be considered to define a patient as negativized.

Persistent aPL disappearance is a hot topic in the field of APS and further prospective studies are needed to assess successful therapeutic strategies. However, a second level screening in patients with aPL negativization is highly suggested before interrupting oral anticoagulation. Besides, when stopping anticoagulation, a physician should consider that aPL are not the only thrombotic risk factor to develop a thrombotic event in a patient. A throughout cardiovascular risk factor evaluation should always be considered and recommended before stopping anticoagulation treatment.
References


